Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2383230 | 0.99 | HRH4 (0.56) | HRH4MAPKAPK2ALKMAP4K1MEN1 | |
| SCHEMBL2385960 | 0.91 | HRH4 (0.61) | HRH4MAPKAPK2ALKMAP4K1MEN1 | |
| SCHEMBL2385008 | 0.89 | HRH4 (0.66) | HRH4MAPKAPK2MAP4K1MEN1GLA | |
| SCHEMBL2383986 | 0.89 | HRH4 (0.56) | HRH4MAPKAPK2ALK | |
| SCHEMBL2384565 | 0.89 | HRH4 (0.56) | HRH4MAPKAPK2ALK | |
| SCHEMBL2385751 | 0.88 | HRH4 (0.61) | HRH4MAPKAPK2MEN1GLAGAA | |
| SCHEMBL2385134 | 0.86 | HRH4 (0.54) | HRH4MAPKAPK2ALKMAP4K1KMT2A | |
| SCHEMBL2384387 | 0.86 | HRH4 (0.54) | HRH4MAPKAPK2ALKMAP4K1MEN1 | |
| SCHEMBL2386125 | 0.85 | HRH4 (0.53) | HRH4ALKMAP4K1MEN1KMT2A | |
| SCHEMBL2385977 | 0.85 | HRH4 (0.64) | HRH4MAPKAPK2ALKMAP4K1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | claimed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | claimed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885MAPKAPK2 4356/4885ALK 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.